Beigene Ltd at Goldman Sachs Global Healthcare Conference Transcript
Good afternoon. Thank you very much for joining this session. This is Ziyi Chen, China health care analyst at Goldman Sachs. Today, we have John Oyler, founder, CEO and Chairman of BeiGene with us, and also Howard Liang, CFO and Chief Strategy Officer, with us to talk about the recent updates on the BeiGene and overall strategy.
Questions & Answers
Probably start with some of the macro questions because BeiGene is now probably size $7 billion to $8 billion company. It's becoming a really sizable biotech company now. So when we talk about -- when we think of allocating our resources with multiple operation globally, so how are we going to spend the money smartly?
Sure. Maybe I can start. I think that one of the things you mentioned is BeiGene is a global company. To us, this is a global industry. You
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |